Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (January 2022)
11 slides from Microbot Medical's investor presentation, Jan 10, 2022
Slide 1: Microbot Medical: Access-Ability for All
microbot ical ACCESS-ABILITY FOR ALL“ HAREL GADOT Chief Executive Officer, President, and
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the ‘Securities Exchange Act of 1934, as amended, relafing to future events or the future financial performance and operations of Mic
Slide 3: Market Opportunity: U.S. Market for Surgical Robotics
S: MARKET OPPORTUNITY % U.S. Market for Surgical Robotics re 19 Million +15-20% Zaye teed aipovie Done eee (est)
Slide 4: Total Addressable US Market: Endo-Vascular
TOTAL ADDRESSABLE US MARKET: ENDO-VASCULAR >5M PROCEDURES’ WHY LOW PENETRATION? Across Coronary, Peripheral and Neuro + Capital expense = hha a ~~ me “<HoNEROBETEALL + Cumbersome and expensive disposables + Extended set-up time + Large footprint + Dedicated infrastructure * Special training, long le
Slide 5: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS Disposable No capital expense Increases procedure efficiency Small Footprint No dedicated infrastructure required Remote Reduce exposure to radiation and HAIs Allows access in remote facilities Mobile Can be utilized in multiple sites of service Universal Any of
Slide 6: 2021 Milestones
2021 MILESTONES stryker Strategic Collaboration Design Freeze Achieved Design Freeze for the LIBERTY Robotic System, paving the way for the Company to build momentum heading into 2022 and the future pre-clinical and clinical trials. Feasability Studies ‘Announced the results of a second feasibility
Slide 7: Stryker
stryker
Slide 8: Underserved Market: Neuro-Vascular
UNDERSERVED MARKET: NEURO-VASCULAR / | ISCHEMIC STROKE Ae + >400% total growth in Patients Treated over the a past 7 yearst! wa + Leading Cause of long-term disability costing / healthcare $184B in 202021
Slide 9: Moving from a Product-Based Solution...
MOVING FROM A PRODUCT-BASED SOLUTION... stryker’ micr
Slide 10: To World's First Dedicated Robotic Procedural Kit
TO WORLD’S FIRST DEDICATED ROBOTIC PROCEDURAL KIT stryker’ microbot medical f Disposable Kit Efficient total procedure time Remote Access Delivering best-in-class = 2. treatment to everyone everywhere Democratization Eliminating procedural variability
Slide 11: 2022 Goals
2022 GOALS stryker Continuous collaboration for dedicated neurovascular kits Key Opinion Leaders Continue to engage with Key Opinion Leaders (KOLs) and leading academic centers to educate and raise awareness of the LIBERTY Robotic system Pre-Submission Finalize U.S. Food and Drug ‘Administration (FD
Microbot Medical — Investor Presentation (January 2022) on 6ix